Azitra (AZTR) Other Working Capital Changes (2022 - 2026)
Azitra's (AZTR) quarterly Other Working Capital Changes came in at -$76649.0 in Q1 2026, up 1.64% YoY from -$75413.2 in Q1 2025, and down 1.14% on a QoQ basis from -$75782.0 in Q4 2025.
Azitra (AZTR) Other Working Capital Changes (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Other Working Capital Changes data on file, last reported at -$76649.0 in Q1 2026.
- Quarterly Other Working Capital Changes rose 1.64% year-over-year to -$76649.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$303636.0 (up 3.86% YoY) and the FY2025 annual result came in at -$304913.0, up 3.46% from the prior year.
- Other Working Capital Changes retreated to -$76649.0 in Q1 2026, from -$75782.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $40012.0 in Q3 2022 to a low of -$40541.0 in Q4 2022.
- A 5-year average of -$57.71 and a median of -$54.5 in 2023 frame the typical range for Other Working Capital Changes.
- Annual changes were most pronounced in 2024 — Other Working Capital Changes fell 20.4% — and 2025, when it climbed 9.84%.
- Tracing AZTR's Other Working Capital Changes over 5 years: stood at -$65656.0 in 2022, then dropped by 6.34% to -$69817.0 in 2023, then declined by 20.4% to -$84057.0 in 2024, then grew by 9.84% to -$75782.0 in 2025, then fell by 1.14% to -$76649.0 in 2026.
- The last three Other Working Capital Changes figures came in at -$76649.0 (Q1 2026), -$75782.0 (Q4 2025), and -$74948.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Azitra | 2.44 Mn | 2.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -72,999.00 |
| Jun 30, 2026 | -72,999.00 |
| Jun 30, 2026 | -72,999.00 |
| Mar 31, 2026 | -76,649.00 |
| Mar 31, 2026 | -76,649.00 |
| Mar 31, 2026 | -76,649.00 |
| Dec 31, 2025 | -75,782.00 |
| Dec 31, 2025 | -75,782.00 |
| Dec 31, 2025 | -75,782.00 |
| Sep 30, 2025 | -74,948.00 |
| Sep 30, 2025 | -74,948.00 |
| Sep 30, 2025 | -74,948.00 |
| Jun 30, 2025 | -76,257.00 |
| Jun 30, 2025 | -76,257.00 |
| Jun 30, 2025 | -76,257.00 |
| Mar 31, 2025 | -77,926.00 |
| Mar 31, 2025 | -77,926.00 |
| Mar 31, 2025 | -77,926.00 |
| Dec 31, 2024 | -84,057.00 |
| Dec 31, 2024 | -84,057.00 |